Innate Pharma (NASDAQ:IPHA) Receives “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $11.50 price target on the stock. Innate Pharma Stock Performance Shares of Innate Pharma stock opened at $1.96 on Friday. Innate Pharma has a 1 year low […]
HC Wainwright reissued their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $11.50 price target on the stock. Innate Pharma Stock Performance Shares of Innate Pharma stock opened at $1.96 on Friday. Innate Pharma has a 1 year low […]
